CAMP4 Therapeutics Corporation Common Stock
CAMPCAMP4 Therapeutics Corporation is a biopharmaceutical company focused on developing genetic medicines using its proprietary Gene Journey platform. The company's technology aims to understand and control gene expression to create targeted therapies for rare and serious diseases. CAMP4 is dedicated to advancing precision medicine approaches to address unmet medical needs.
Company News
CAMP4 Therapeutics granted non-qualified stock options to purchase 39,000 shares to three newly hired employees as inducement for employment. The options have a 10-year term, an exercise price of $3.96 per share, and will vest over four years with 25% vesting after one year followed by monthly installments.
CAMP4 Therapeutics granted 8,000 non-qualified stock options to a newly hired employee on February 16, 2026, with an exercise price of $3.85 per share. The options vest over four years with a ten-year term, reflecting the company's continued hiring and growth in its RNA-targeting therapeutics pipeline.
CAMP4 Therapeutics secured a private placement of up to $100 million to advance its first-in-class treatment for SYNGAP1-related disorders, with $50 million in upfront proceeds and potential additional funding contingent on clinical milestones.
CAMP4 presented positive data from its SYNGAP1-related disorders and urea cycle disorders programs, including increased protein levels in non-human primates and favorable safety data from a Phase 1 trial.
The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.
